Long-term follow-up after a gene-modified cell treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a gene-modified cell product through a St. Jude study in the last 15 years
- You (and your legal guardian or representative, if needed) can give written consent
- You are willing to be contacted and take part in long-term follow-up
- You understand you are joining follow-up research rather than receiving the original treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people with sickle cell disease or thalassemia who have had a bone marrow transplant or gene therapy in the past 15 years. It aims to monitor their health over time to understand long-term effects.
This study looks at the long-term health of people who were treated for medulloblastoma with craniospinal radiation at St. Jude Children's Research Hospital. It aims to understand how they are doing years after treatment.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Hear when a new Relapsed Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.